Best Dividend Stocks to Buy in 2026: 12 Picks
for Steady US Income
I started paying real attention to dividend stocks about three years ago, after I did the math on my savings account and realized I was losing money to inflation every single month. That's a boring realization, but it's the one that actually gets people to change how they invest. Growth stocks are fun to talk about at parties. Dividend stocks are what actually pay your electric bill in retirement.
Right now, in the second half of 2026, dividend investing has an interesting setup. The S&P 500's average dividend yield is sitting near 1.1%, which is close to multi-decade lows — meaning the index itself pays you almost nothing just for holding it. Meanwhile the 10-year Treasury note is yielding somewhere just under 4.5%, down from a recent high above 4.6% back in May. That gap matters. When bond yields are elevated, dividend stocks have to work harder to justify themselves, and a lot of "high yield" names out there are only high because the stock price has already fallen and the market is pricing in trouble.
So this isn't going to be a generic "here are 20 dividend stocks" list where I just paste tickers and yields. I want to walk through why each of these companies actually earns a spot on a list like this, where the risk sits, and — just as important — where I'd personally be more cautious.
Why Yield Alone Is a Trap
Before naming names, I want to get one thing out of the way, because I've made this mistake myself early on: chasing the highest yield you can find is a great way to lose money. A stock yielding 9% isn't giving you a gift. In most cases the market has already decided that dividend is at risk, and the "high yield" is really just a depressed share price doing the math for you.
The metric I actually pay attention to is the payout ratio — how much of a company's earnings or cash flow is going out the door as dividends. A payout ratio comfortably under 75-80% generally means there's room to keep paying even if a bad quarter shows up. Above that, and especially above 100%, the dividend is often being funded by debt or asset sales, which doesn't end well.
I also look at how many consecutive years a company has raised its dividend. Anyone who's increased their payout for 25+ years (the "Dividend Aristocrats") or 50+ years (the "Dividend Kings") has been through recessions, rate hikes, and industry downturns without blinking. That track record tells you more than a single quarter's numbers ever could.
There's no single official definition of what counts as a "high yield" dividend stock, which honestly causes more confusion than it should. Some investors use the S&P 500's average yield as the baseline and call anything roughly double that "high yield." Others use the 10-year Treasury yield as the bar — if a stock doesn't at least match what a government bond pays, why take on stock-market risk for the income? I lean toward the second definition, personally, but I think either approach is reasonable as long as you're consistent about applying it.
What I'd actively warn against is the reverse logic — starting with "I want a big number" and working backward to find a stock that yields it. That's how people end up owning a company three months before it slashes its payout in half. The yield is the last thing I look at, not the first.
Dividend Growth vs. High Yield: Which Strategy Actually Fits
You
Before getting into the list, it's worth being honest that "best dividend stocks" means different things depending on what you're actually trying to do with the money, and conflating the two approaches is where a lot of beginners get tripped up.
If you need income now — you're retired, or close to it, or you're just supplementing a paycheck — a higher current yield with a manageable payout ratio matters more to you than growth. You want the cash flow today, not a promise of more cash flow in fifteen years.
If you're still working and reinvesting — dividend growth matters more than the starting yield. A stock yielding 2% today but raising its payout 10% a year will out-earn a stock yielding 5% today with flat payouts within roughly a decade, just from the compounding math alone. This is the "yield on cost" concept — the yield relative to what you originally paid, which climbs every year the dividend gets raised, even though the stock's current yield (relative to today's price) might look unchanged.
Most of the picks below lean toward the second camp — durable businesses with room to keep raising payouts — with a couple of higher-current-yield names mixed in for people who want income sooner rather than later. I've tried to flag which is which as I go.
1. AbbVie (ABBV) — The Dividend King With a Growth Engine
Current price: ~$259 (as of July 24, 2026 close) | Analyst price target: ~$267 average, based on 31 analysts polled by S&P Global — a "Buy" consensus implying roughly 3% upside | What's new: AbbVie just closed a $10.9 billion acquisition of Apogee Therapeutics, adding a promising immunology drug candidate (zumilokibart, being studied for atopic dermatitis) to its pipeline. Piper Sandler recently raised its price target to $289, citing stronger-than-expected Skyrizi estimates for 2026 and beyond.
AbbVie doesn't get talked about as a "growth stock," but honestly, it should. This is a Dividend King with 53 consecutive years of dividend increases when you count its time as part of Abbott Labs before the 2013 spinoff. Its forward yield sits around 3.3%, roughly three times what the S&P 500 pays out.
What actually convinced me to put AbbVie at the top of this list isn't the yield history — it's that the company solved a problem that used to scare every dividend investor away from it. For years, the entire bear case on AbbVie was "what happens when Humira loses patent protection?" That happened, and instead of falling apart, AbbVie's newer drugs — Rinvoq and Skyrizi, both treating autoimmune conditions — grew into multi-billion-dollar franchises in their own right, with label expansions still rolling out for conditions like Crohn's disease. The pipeline concern that used to be the whole story around this stock has genuinely faded.
That doesn't mean it's risk-free. Big pharma always carries regulatory and pricing-policy risk, and a chunk of AbbVie's EPS volatility on paper comes from accounting charges tied to acquired research programs — not from the actual business underperforming, but it can spook investors who don't dig into the footnotes.
2. Chevron (CVX) — Old-School Energy Reliability
Current price: ~$190 | Analyst price target: ~$217 average, based on 31 analysts — a "Buy" consensus implying roughly 14% upside | What's new: Chevron was recently assumed with an Overweight rating at Piper Sandler, and TD Cowen raised its target to $200. The company is working through the integration of its Hess acquisition and continues to lean on the Permian Basin for capital-efficient production growth.
Chevron just delivered its 39th consecutive annual dividend increase, one of the longest active streaks in the entire oil and gas sector. I'll admit energy stocks aren't my favorite thing to hold long-term because of how tied they are to commodity prices outside anyone's control, but Chevron's integrated model — meaning it does everything from drilling to refining to selling — gives it more stability than a pure exploration company.
The company has guided toward growing free cash flow at more than a 10% compound annual rate through 2030, assuming oil holds around $70 a barrel. That assumption is obviously the whole ballgame — if oil prices crater, that math changes fast. But Chevron's low-cost production base means it can stay profitable at oil prices that would hurt smaller competitors, and the dividend has survived multiple oil crashes already.
3. Enbridge (ENB) — Canadian Pipeline, US-Style Reliability
Current price: ~C$76 on the Toronto exchange (roughly ~$55 on the NYSE in US dollars) | Analyst price target: ~C$79 average, based on 28 analysts — implying modest upside, though estimates vary noticeably depending on which data provider and currency you're looking at, so treat this one as a range rather than a precise number | What's new: Scotiabank, TD Securities, and Morgan Stanley have all raised their targets on Enbridge in recent weeks, and the company is set to report earnings on July 31, 2026.
Enbridge offers a dividend yield around 5.4%, and it's raised that payout for 31 straight years. What I like here is the business model itself: Enbridge doesn't actually take on much commodity price risk the way an oil producer does. It gets paid to move oil and gas through its pipeline network under long-term contracts, so its cash flow looks a lot more like a toll-road business than an energy-trading business.
The risk with Enbridge is regulatory and political — pipeline projects face constant permitting battles, and being a Canadian company means US investors also carry a little currency exposure. Still, for the yield, this is one of the steadier income names in the energy space.
4. Realty Income (O) — The "Monthly Dividend Company"
Current price: ~$64 | Analyst price target: ~$68 average, based on 24 analysts — a "Hold" consensus implying roughly 6% upside | What's new: Realty Income recently closed the recast and expansion of its credit facility, and is reportedly among the parties in talks with British supermarket chain Morrisons over a roughly £600 million UK real estate deal.
Realty Income has built an entire brand around paying dividends monthly instead of quarterly, which sounds like a marketing gimmick until you actually own it and see the cash show up every month like a paycheck. It owns over 15,500 properties across the US, UK, and parts of continental Europe, and its tenant list is a genuinely interesting mix — 7-Eleven convenience stores are its single largest tenant, but it also holds a roughly 22% stake in the Bellagio hotel and casino complex in Las Vegas.
As a REIT (real estate investment trust), Realty Income is legally required to pass most of its taxable income through to shareholders as dividends, which is part of why the yield tends to run higher than a typical S&P 500 company. The properties it owns are mostly standalone retail buildings rather than mall-based stores, which matters — standalone retail (think pharmacies, dollar stores, gas stations) has held up much better against e-commerce disruption than traditional mall retail.
5. Altria Group (MO) — Boring, and That's the Point
Current price: ~$73 | Analyst price target: ~$70 average — a "Hold/Neutral" consensus, with targets scattered widely between roughly $47 and $73 depending on the analyst, reflecting real disagreement about how much more room the stock has | What's new: New CEO William Gifford Jr. has been steering the company's continued push into smoke-free products, while cigarette volumes keep sliding — the core tension that shapes every price target on this stock.
Altria's dividend yield is close to 6%, the highest on this list, and the payout is better supported than the headline number might suggest — the cash payout ratio runs around 82%, with adjusted earnings expected to keep growing at a mid-to-high single-digit pace for the next few years. The stock's beta (a measure of volatility relative to the market) sits around 0.51, meaning it historically moves about half as much as the broader market — useful if you want income without the stomach-churning swings.
I won't pretend the tobacco industry doesn't carry obvious long-term headwinds — declining smoking rates, regulatory pressure, litigation risk. That's exactly why the yield is where it is; the market is pricing in a slow, managed decline rather than growth. A leadership transition earlier this year adds a bit of near-term uncertainty too, but Altria's cash-generating core business doesn't hinge on any single executive.
6. Verizon (VZ) — Telecom Income, Trading Below Fair Value
Current price: ~$47 (jumped after Q2 earnings) | Analyst price target: ~$52 average, based on 26 analysts — a "Buy" consensus implying roughly 9% upside | Recent support/resistance (pre-earnings): support had been forming around $42-43.50, with resistance around $46.75-49 — the stock has since pushed through that resistance zone following its earnings beat, so those levels may need to reset higher | What's new: Verizon beat Q2 2026 estimates, raised its full-year guidance for revenue, EPS, and free cash flow, launched new "Simplicity" plans and Verizon One converged offerings, and raised its share buyback target to up to $4.5 billion for the year.
Verizon currently trades a meaningful amount below Morningstar's fair value estimate on the stock, and it's one of the higher-yielding names among analysts' preferred dividend picks for 2026. What stood out to me digging into this one is that Verizon directed the majority of its 2025 cash flow toward the dividend and still found room to repurchase billions in shares in the first quarter of 2026 — that's not a company straining to cover its payout.
The competitive backdrop in wireless remains genuinely tough — customer churn (people switching providers) is still elevated industry-wide — but Verizon has reportedly been doing a noticeably better job attracting new subscribers than it was a year ago, which matters more for the stock's direction than the churn number in isolation.
7. Johnson & Johnson (JNJ) — The Definition of Boring-and-
Reliable
Current price: ~$268 | Analyst price target: ~$270-279 average depending on the source, based on 17-24 analysts — a "Buy" consensus implying modest upside | What's new: J&J beat Q2 2026 earnings estimates (its ninth straight beat) on July 15, raised its full-year 2026 guidance, and announced positive Phase 3 trial results for a combination therapy (Tecvayli plus Talvey) in relapsed/refractory multiple myeloma.
J&J shows up on basically every conservative dividend list for a reason: diversified healthcare revenue (pharmaceuticals plus medical devices), a fortress balance sheet, and decades of dividend increases. It's not the stock that's going to double your money, and it's not trying to be. It's the stock you own so that a chunk of your portfolio doesn't need your attention.
8. Procter & Gamble (PG) — Consumer Staples, Pricing Power
Current price: ~$147-152 (trading in a fairly tight range ahead of earnings) | Analyst price target: ~$163-172 average — a "Buy" consensus implying meaningful upside, though the target has been drifting down over the past year | What's new: P&G reports fiscal Q4 2026 earnings on July 29, 2026. The company recently absorbed a roughly $1 billion cost headwind tied to higher Middle East oil prices, and its SK-II skincare brand has seen sales in Greater China drop around 30%.
P&G owns categories of products people buy regardless of what the economy is doing — toothpaste, laundry detergent, diapers. That's the entire appeal of consumer staples as a sector: demand doesn't disappear in a recession the way it does for, say, vacation bookings or new cars. P&G has also shown real pricing power over the past few years, passing along cost increases without losing much market share, which is exactly the kind of thing that protects a dividend during inflationary stretches.
9. Broadcom (AVGO) — The Unusual Pick on This List
Current price: ~$383 (as of July 27, 2026) | Analyst price target: ~$525 average, based on 48 analysts — a "Strong Buy" consensus implying roughly 37% upside, though estimates range enormously from around $216 to $675, which tells you how divided opinion is on how far the AI cycle can run | What's new: Broadcom and Samsung just signed a long-term AI chip collaboration reportedly worth up to $200 billion through 2030, on top of an earlier reported ~$30 billion custom chip deal with Apple running through 2031. AI semiconductor revenue hit $10.8 billion last quarter, up 143% year-over-year.
Broadcom is the name here that surprises people, because most investors think of it as an AI and semiconductor growth stock, not a dividend stock. But it's quietly built a real dividend growth track record while still riding the AI infrastructure buildout. The risk is obvious — semiconductor demand is cyclical, and if AI capital spending cools off the way some analysts have been warning about this year, Broadcom's growth story (and possibly its valuation) takes a hit before the dividend would. I'd treat this one as a smaller position size than the others on this list — you're getting dividend growth potential, but you're also taking on real cyclical and sentiment risk that names like JNJ or P&G simply don't have.
10. Coca-Cola (KO) — The Classic Starter Dividend Stock
Current price: ~$82 (heading into Q2 earnings on July 28, 2026) | Analyst price target: ~$88 average, based on 24 analysts — a "Buy" consensus implying roughly 7% upside | What's new: Coke's 2026 FIFA World Cup marketing push and new AI-driven vending machine marketing have reportedly been driving a real sales bump, but the company's Fairlife dairy subsidiary was hit by a ransomware attack that halted production. Coca-Cola is also reportedly lining up bankers for a planned 2027 IPO of one of its India bottling partners.
If you're building a dividend portfolio from scratch, Coca-Cola is one of the names people reach for first, and there's a good reason beyond brand recognition: it's a Dividend King with an enormous global distribution network that's nearly impossible for a competitor to replicate from scratch. Beverage consumption isn't going anywhere, and Coke's push into non-soda categories (water, sports drinks, coffee) has diversified it away from being purely a sugary-soda story.
11. McDonald's (MCD) — Real Estate Disguised as a Burger
Chain
Current price: ~$265 (trading near its 52-week low) | Analyst price target: widely scattered, roughly $320-350 depending on the analyst — still a net "Buy" lean, but several firms (Wells Fargo, Evercore, UBS, Deutsche Bank) have all trimmed their targets in the past month | Support/resistance: support sits around the 52-week low near $259-261, with resistance around $266-270 (the 20-day moving average) — the stock needs a daily close above that level to signal the recent weakness is stabilizing | What's new: Franchise checks have flagged softer US traffic trends, and multiple analysts have cut price targets citing consumer spending pressure, even as McDonald's declared its regular $1.86-per-share quarterly dividend.
People forget that McDonald's makes an enormous amount of its money from real estate and franchise fees, not from flipping burgers directly. That distinction matters for dividend reliability — franchise and rent income is far steadier than restaurant operating margins, which is part of why McDonald's has kept raising its dividend through periods that hurt other restaurant chains badly.
12. Enterprise Products Partners (EPD) — Midstream Energy
Without the Drilling Risk
Current price: ~$38.50 | Analyst price target: ~$41 average, based on 13 analysts — implying roughly 7-8% upside | What's new: Rising natural gas demand tied to AI data centers has helped push EPD up more than 20% year-to-date. The company reports Q2 2026 earnings on July 30, 2026, and co-CEO A.J. Teague recently announced plans to retire effective January 2027.
Enterprise Products Partners belongs to a category called midstream energy — companies that own the pipelines, storage terminals, and processing facilities that move oil and gas around, rather than companies actually drilling for it. Most midstream companies (including EPD) are structured as master limited partnerships, which are required to pass most of their pretax earnings straight through to unitholders as distributions. That structure is exactly why midstream names tend to carry noticeably higher yields than integrated majors like Chevron or ExxonMobil, while also having steadier cash flow than a pure exploration company, since revenue is locked in through long-term, fixed-fee contracts rather than fluctuating with the daily price of oil.
One note if you're not familiar with MLPs: they come with a slightly different tax form (a K-1 instead of a standard 1099-DIV), which trips up a lot of first-time buyers around tax season. Worth knowing before you buy, not after.
How I'd Actually Build a Portfolio Around This List
A few practical rules I follow, for what it's worth:
Cap any single sector at around three positions. Energy, healthcare, and consumer staples all show up multiple times on this list for a reason, but if your entire dividend portfolio is secretly just "energy stocks plus one REIT," you're not diversified, you're just concentrated with extra steps.
Reinvest the dividends if you don't need the income yet. Compounding is where the real long-term return comes from with these names — the yield alone rarely beats inflation by much on its own, but yield plus reinvestment plus modest dividend growth compounds into something meaningful over a decade.
Revisit payout ratios once or twice a year, not every quarter. Obsessively checking these numbers monthly just leads to overreacting to noise. A single soft quarter doesn't break a 30-year dividend streak.
Size your positions to the risk, not just the yield. This is the mistake I made early on — I put too much money into the highest-yielding name on my list instead of spreading it based on how confident I actually was in the business. A 6% yielder and a 3% yielder can both deserve a spot in your portfolio, just not the same-size spot.
A Quick Word on Taxes, Since Nobody Else Mentions It
One thing that genuinely surprised me the first year I owned a mix of REITs, MLPs, and regular corporations: they don't all get taxed the same way, and it's not something your broker will proactively explain to you.
Regular dividend-paying corporations like AbbVie, Chevron, or Coca-Cola typically pay "qualified dividends," which get taxed at the same lower long-term capital gains rates most investors are used to, as long as you've held the shares long enough (generally more than 60 days around the ex-dividend date).
REITs like Realty Income are a different story. Because REITs don't pay corporate income tax as long as they distribute most of their earnings, the dividends they pass on to you are often taxed as ordinary income instead — which can mean a noticeably higher tax bill depending on your bracket. That doesn't make REITs a bad investment, it just means the after-tax yield is usually lower than the headline yield suggests, and it's worth running the numbers for your own tax situation rather than assuming REIT income behaves like other dividend income.
MLPs like Enterprise Products Partners are the third category, and the one that trips people up most. You'll get a Schedule K-1 form instead of the standard 1099-DIV, the distributions are often partially tax-deferred (treated as a return of capital rather than immediate income), and depending on how much you own, MLPs held inside a retirement account can occasionally trigger something called Unrelated Business Taxable Income (UBTI) — a tax on retirement accounts that most people have never heard of until it shows up. None of this makes MLPs off-limits, but it's exactly the kind of detail that's easy to skip past in a list like this and then get blindsided by come tax season.
How I Personally Track These Positions
I'm not going to pretend I have some elaborate system — a simple spreadsheet tracking cost basis, current yield, payout ratio, and years of consecutive increases gets you 90% of the way there. The one habit that's actually made a difference for me is checking payout ratios against the company's own quarterly earnings release rather than relying purely on a third-party summary, since some data sites lag behind the latest quarter or use slightly different definitions of "earnings" (GAAP versus adjusted, for instance) that can make the same company look safer or riskier depending on the source.
I'd also encourage setting a calendar reminder around each company's typical earnings date rather than checking obsessively. Dividend stocks are, by design, meant to be a lower-maintenance part of a portfolio — if you're refreshing the stock price five times a day, you're probably better suited to a different investing style entirely.
The Honest Downside Nobody Puts in These Lists
Dividend stocks aren't magic, and I want to say that plainly. They can still fall in price, some of them can and do cut their dividends when things go badly enough (ask anyone who held certain energy or REIT names in 2020), and "safe" is always relative, never guaranteed. Rising interest rates can also make dividend stocks less attractive on a relative basis, since investors can get a similar or better yield from a Treasury bond with essentially none of the stock-price risk — which is part of why that 4.5% 10-year yield mentioned earlier is worth watching, not just skimming past.
I'd also gently push back on anyone treating this list, or any list like it, as a buy signal on its own. Prices move. What was a reasonable entry point when I'm writing this in July 2026 might not be one by the time you're reading it. Check current prices, current payout ratios, and honestly just check whether the story I described above is still true before putting money in.
One more thing worth saying plainly: past dividend history is genuinely useful information, but it's not a guarantee of future behavior. Every one of these companies could face a scenario five or ten years from now that none of us are currently pricing in — a regulatory shift, a new competitor, a technology disruption, a leadership decision that goes badly. Dividend Aristocrat and Dividend King status get earned over decades, but they can be lost in a single bad year, and it has happened before to companies that looked just as "safe" as anything on this list.
If I had to boil down everything above into one habit worth keeping: don't marry a stock because of its yield. Check in on the business itself every so often — not the price, the actual business — and be willing to sell if the reason you bought it stops being true, even if the yield still looks attractive on paper.
Disclaimer:
This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. I'm not a licensed financial advisor. Dividend payments are never guaranteed and can be reduced or eliminated at a company's discretion. Please do your own research and consult a qualified financial professional before making investment decisions.